Announcement PDF Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity INVION LIMITED ABN 76 094 730 417 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director DR JAMES CAMPBELL Date of last notice 11 December 2015 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. Direct (sale) / Indirect (purchase) Indirect holdings are Fusion Biosciences Pty Ltd of which Dr Campbell is a director; and James A Campbell and Kelly F Windmill of which Dr Campbell is a beneficiary. Dr Campbell completed an on-market transfer of shares between direct and indirect holdings. Date of change 26 June 2017 Total No. of securities held prior to change 3,104,794 fully (directly held). paid Ordinary Shares 125,000 fully (indirectly held). paid Ordinary Shares 1,500,000 share options with an exercise price of $0.09 and an expiry date of 9 November 2017. + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Appendix 3Y Change of Director’s Interest Notice Class Fully paid Ordinary Shares Number acquired 256,236 indirect shares acquired Number disposed 256,236 direct shares disposed Value/Consideration $0.002 per share Total No. of securities held after change 2,848,558 fully (directly held). paid Ordinary Shares 381,236 fully (indirectly held). paid Ordinary Shares Note: If consideration is non-cash, provide details and estimated valuation 1,500,000 share options with an exercise price of $0.09 and an expiry date of 9 November 2017. Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back On-market transfer between holdings. Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract n/a Nature of interest n/a Name of registered holder (if issued securities) n/a Date of change n/a No. and class of securities to which n/a interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired n/a Interest disposed n/a + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 Appendix 3Y Change of Director’s Interest Notice Value/Consideration n/a Interest after change n/a Note: If consideration is non-cash, provide details and an estimated valuation Part 3 – +Closed period Were the interests in the securities or contracts detailed No. above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade n/a to proceed during this period? If prior written clearance was provided, on what date was this n/a provided? + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3